$Karyopharm Therapeutics (KPTI.US)$ Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025. Phase 1 trial data showed pr...
$Karyopharm Therapeutics (KPTI.US)$Reuters· 5 mins ago Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
$Karyopharm Therapeutics (KPTI.US)$This dude was hired when stock price was 10 dollar. Now we are screwed. looks like a let resign. He’s good controller but probably a really bad CFO.
$Karyopharm Therapeutics (KPTI.US)$so we would be back in profit, cash flow for the medicine would make shares back to 8 to 10 zone. No idea what’s the plan. Keep bleeding to death?
Karyopharm Therapeutics Stock Forum
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
No comment yet